PVLA Return on Tangible Equity | Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. (PVLA) Return on Tangible Equity

2026-06-30: Return Tang Equity -28.45%.
2026-03-31: Return Tang Equity -21.22%.
2025-12-31: Return Tang Equity -149.07%.
2025-09-30: Return Tang Equity -85.19%.

Complete source-backed return tang equity history.

Available history: 2013-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical Return Tang Equity

Date	Return Tang Equity
2026-06-30	-28.45%
2026-03-31	-21.22%
2025-12-31	-149.07%
2025-09-30	-85.19%
2025-06-30	-59.40%
2025-03-31	-41.53%
2024-12-31	-27.85%
2024-09-30	-28.79%
2024-06-30	-26.22%
2024-03-31	-38.16%
2023-12-31	-25.09%
2023-09-30	-91.97%
2023-06-30	-66.78%
2023-03-31	-267.56%
2022-12-31	35.49%
2022-09-30	-97.04%
2022-06-30	-93.56%
2022-03-31	-87.31%
2021-12-31	-90.12%
2021-09-30	-93.97%
2021-06-30	-103.49%
2021-03-31	-98.87%
2020-12-31	-119.99%
2020-09-30	-54.02%
2020-06-30	-25.52%
2020-03-31	-37.58%
2019-12-31	-49.60%
2019-09-30	-176.24%
2019-06-30	-204.98%
2019-03-31	-94.11%
2018-12-31	-66.99%
2018-09-30	-15.08%
2018-06-30	-15.34%
2018-03-31	-36.23%
2017-12-31	-153.16%
2017-09-30	-695.37%
2017-06-30	-330.34%
2017-03-31	-147.66%
2016-12-31	-90.38%
2016-09-30	-60.80%
2016-06-30	-45.23%
2016-03-31	-53.41%
2015-12-31	-45.16%
2015-09-30	-45.54%
2015-06-30	-120.42%
2015-03-31	-89.79%
2014-12-31	-54.70%
2014-09-30	628970.13%
2014-06-30	-36643.72%

Annual Return Tang Equity

Date	Return Tang Equity
2025-12-31	-149.07%
2024-12-31	-27.85%
2023-12-31	-25.09%
2022-12-31	35.49%
2021-12-31	-90.12%
2020-12-31	-119.99%
2019-12-31	-49.60%
2018-12-31	-66.99%
2017-12-31	-153.16%
2016-12-31	-90.38%
2015-12-31	-45.16%
2014-12-31	-54.70%
2014-06-30	-156.90%
2013-12-31	11.32%

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Braveheart Bio, Inc. (BRVE)	United States	$2.106B
Bausch Health Companies Inc. (BHC)		$2.113B	-1.68
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
OCULAR THERAPEUTIX, INC (OCUL)	United States	$2.159B	-7.15
Prestige Consumer Healthcare Inc. (PBH)	United States	$2.163B	13.03
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12